Benzimidazole Derivatives as PI3 Kinase Inhibitors
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application 14/164,414, filed Jan 27, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,062,003 | Benzimidazole Derivatives as PI3 Kinase Inhibitors In force · High confidence | GlaxoSmithKline LLC | In force | High confidence | ||
| US 9,156,797 | Benzimidazole Derivatives As PI3 Kinase Inhibitors In force · High confidence | GlaxoSmithKline LLC | In force | High confidence | ||
| US 10,314,845 | Benzimidazole Derivatives as PI3 Kinase Inhibitors In force · High confidence | GlaxoSmithKline LLC | In force | High confidence | ||
| US 10,660,898 | Benzimidazole Derivatives as PI3 Kinase Inhibitors In force · High confidence | GlaxoSmithKline LLC | In force | High confidence | ||
| US 9,872,860 | Benzimidazole Derivatives As PI3 Kinase Inhibitors Lapsed Jan 23, 2026 on the fee record Ended Jan 23, 2026 · High confidence | GlaxoSmithKline LLC | Lapsed Jan 23, 2026 on the fee record | Ended Jan 23, 2026 | High confidence | |
| US 8,674,090 | Benzimidazole Derivatives As PI3 Kinase Inhibitors Lapsed Mar 18, 2026 on the fee record Ended Mar 18, 2026 · High confidence | GlaxoSmithKline LLC | Lapsed Mar 18, 2026 on the fee record | Ended Mar 18, 2026 | High confidence | |
| US 8,865,912 | Benzimidazole Derivatives As PI3 Kinase Inhibitors Lapsed Oct 21, 2026 on the fee record Ended Oct 21, 2026 · Low confidence | GlaxoSmithKline LLC | Lapsed Oct 21, 2026 on the fee record | Ended Oct 21, 2026 | Low confidence | |
| Application 13/876,853 | Benzimidazole Derivatives as PI3 Kinase Inhibitors Abandoned Abandoned Sep 24, 2013 | GlaxoSmithKline LLC | Abandoned | Abandoned Sep 24, 2013 |
8 of 8 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by GlaxoSmithKline LLC.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.